Brief: Novakand Pharma Applies For Nasdaq's Approval Of Continued Listing
13/02/2026 06:15
Feb 13 (Reuters) - Novakand Pharma AB NOVKAN.ST: SAID ON THURSDAY APPLIES FOR NASDAQ’S APPROVAL OF CONTINUED LISTING OF THE COMBINED COMPANY POST A COMPLETED REVERSE TAKEOVER WITH SVF VACCINES Source text: ID:nMFN4xxsh4 Further company coverage: NOVKAN.ST (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Novakand Pharma AB
See all newsBrief: Nasdaq Decides To Delist Novakand From First North Growth Market
Brief: Novakand Pharma Extends Peter Selin's CEO Employment
Brief: Novakand Board Proposes New Business Direction, Relisting
Brief: Novakand Pharma Evaluates Options After Decision Not To Execute Reverse Take Over
Brief: Nasdaq Rejects Novakand's Application For Continued Listing